TL;DR
Researchers have characterized the distinct binding preferences of two isoforms of the TRIM33 protein (TRIM33α and TRIM33β) for histone modifications, revealing differences in how they interact with acetylated lysine. This work led to the development of a new assay that identified four potential small-molecule ligands for TRIM33, paving the way for developing chemical probes to study its cellular roles.
What Problem Does This Paper Address?
Histone modifications are crucial for regulating gene expression, and proteins that "read" these marks, like those with Plant Homeodomain (PHD) and Bromodomain (BRD) modules, are key players in epigenetics. TRIM33 is one such protein, featuring both PHD and BRD domains. However, TRIM33 exists in at least two isoforms, TRIM33α and TRIM33β, which differ in a specific region (the BC loop of the BRD). It was unclear how these structural differences affected their ability to bind to histone modifications and whether they could be targeted by small molecules. This paper aims to elucidate these differences, understand their binding specificities, and identify potential drug-like molecules that can interact with these domains.
Methods
The study employed a multi-pronged approach:
- X-ray Crystallography: To visualize the 3D structures of the TRIM33β PHD-BRD cassette, both alone and bound to histone peptides. This provided crucial insights into the structural differences between the isoforms, particularly concerning a key residue (N1039) in the BRD.
- Biophysical Assays (AlphaScreen and ITC): These techniques were used to quantitatively measure the binding affinities of various modified histone peptides to the TRIM33 PHD-BRD cassettes. AlphaScreen is a high-throughput screening method, while Isothermal Titration Calorimetry (ITC) provides more detailed thermodynamic data.
- Computational Studies (Molecular Dynamics Simulations and Docking): MD simulations were used to explore the dynamic interactions between the TRIM33 reader domains and histone peptides, providing insights into the nature of these interactions (hydrophilic vs. hydrophobic). Molecular docking was used to predict how potential small-molecule ligands might bind to the TRIM33 BRD.
- Mutagenesis Studies: Specific amino acid residues in the PHD and BRD domains were mutated to understand their contribution to histone peptide binding.
Datasets
Not explicitly discussed as "datasets" in the traditional machine learning sense. The study utilized:
- Histone Peptides: A library of modified histone H3 peptides (e.g., H3<sub>1-27</sub>K18Ac, H3<sub>1-27</sub>K9Me<sub>3</sub>K18Ac) were synthesized and used as binding partners.
- Protein Constructs: Recombinant PHD-BRD cassettes of TRIM24, TRIM33α, and TRIM33β were expressed and purified.
- Compound Libraries: A virtual screen was performed on the Maybridge fragment library and the PPI-Net collection. Subsequently, a subset of these compounds was tested, leading to the identification of four lead compounds (8-11).
Key Insights and Ideas
- Isoform-Specific BRD Structure: The key difference lies in the orientation of residue N1039 in the BRD. In TRIM33β, it's positioned to interact with acetylated lysine (KAc), while in TRIM33α, it's oriented away from the binding pocket due to a 17-amino acid insertion.
- Shared Affinity for Key Modifications: Despite structural differences, both TRIM33 isoforms exhibit similar binding affinities for H3K18Ac and a strong preference for the dual-modified peptide H3K9Me<sub>3</sub>K18Ac. This suggests a cooperative binding mechanism.
- TRIM33 as a Challenging Target: The study highlights that TRIM33's reader domains are difficult to target with small molecules, as indicated by a low hit rate in their screening assays.
- Compound 8 as a Promising Lead: Compound 8, featuring a benzoimidazolone moiety, shows selective binding to TRIM33 BRDs and is proposed to act as a KAc mimic, making it a valuable starting point for developing more potent and selective ligands.
Key Results
- X-ray crystal structures revealed the distinct positioning of N1039 in TRIM33β (interacting with KAc) versus TRIM33α (outside the pocket).
- Both TRIM33α and TRIM33β PHD-BRD cassettes showed similar affinities for H3<sub>1-27</sub>K18Ac (IC<sub>50</sub> ~1.2 µM and ~0.96 µM, respectively) and a higher affinity for H3<sub>1-27</sub>K9Me<sub>3</sub>K18Ac (IC<sub>50</sub> ~0.78 µM and ~0.62 µM, respectively).
- Mutagenesis studies confirmed the critical role of W828/W889 in PHD-mediated KMe<sub>3</sub> recognition and N980/N1039 in BRD-mediated KAc recognition.
- An AlphaScreen assay identified four potential small-molecule ligands (compounds 8-11) for the TRIM33 PHD-BRD cassette.
- Compound 8 demonstrated selective binding to TRIM33 BRDs and was predicted to bind to the KAc pocket, with potential interactions with E981 and N1039.
Limitations and Future Work
- Low Hit Rate and Affinity: The study acknowledges the difficulty in finding high-affinity ligands for TRIM33, with a low hit rate (0.22%) in their screening. The identified ligands also exhibit relatively moderate affinities.
- Isoform Selectivity: While compound 8 shows promise, further work is needed to develop ligands that are highly selective for either TRIM33α or TRIM33β.
- In Vivo Validation: The identified ligands have primarily been validated in vitro. Future work should focus on assessing their efficacy and specificity in cellular and in vivo models.
- PROTAC Development: The authors suggest that the identified ligands could be used to develop Proteolysis Targeting Chimeras (PROTACs) to recruit TRIM33's E3 ligase activity for targeted protein degradation, which would require further investigation.
- Understanding Biological Activity: The precise biological consequences of targeting TRIM33 isoforms with these ligands remain to be explored.
Summary updated